Regions :: Western Europe
Mylan to acquire Abbott's non-US branded generics pharma business
11:35 AM MDT | July 18, 2014 | Natasha Alperowicz
Mylan (Pittsburgh) has entered into a definitive agreement with Abbott to acquire Abbott's non-US developed markets specialty and branded generics business in an all-stock transaction. Abbott will receive 105 million shares of the combined company, worth approximately $5.3 billion based on Mylan's closing price of $50.20 on 11 July, representing an approximately 21% ownership stake. The transaction will further diversify Mylan's business and strengthen its commercial platform outside the United States, building new opportunities for growth and additional sales...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee